Overview: Alpha-Fetoprotein Tumor Marker TestIntroduction: The Alpha-Fetoprotein Tumor Marker Test measures alpha-fetoprotein (AFP) to detect or monitor liver, testicular, or ovarian cancers, which may cause pain or weight loss. Aligned with 2023 NCCN guidelines, it uses an immunoassay for high sensitivity, aiding in cancer diagnosis and monitoring. This test is critical for guiding oncology treatments, assessing tumor response, and improving outcomes in cancer care.
Other Names: AFP Tumor Assay, Tumor Marker AFP Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for cancer screening.
Historical Milestone: AFP was linked to liver cancer in the 1960s. Immunoassays emerged in the 1980s, and by the 2000s, standardized assays improved tumor monitoring.
Purpose: Diagnoses or monitors liver, testicular, or ovarian cancers, guides therapy, and assesses tumor response in patients with pain or weight loss.
Test Parameters: 1. Alpha Fetoprotein (Tumor Marker)
Pretest Condition: No fasting required. Collect serum at any time. Report symptoms like abdominal pain, weight loss, or cancer history.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document cancer history, symptoms like pain or weight loss, or family history of tumors. Include current oncology treatments.
Consent: Written consent required, explaining the test's purpose, diagnostic implications, and potential therapy needs.
Procedural Considerations: Uses an immunoassay to measure AFP levels. Results are available in 1-2 days, supporting rapid oncology decisions.
Factors Affecting Result Accuracy: Liver disease or pregnancy may elevate AFP, causing false positives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Elevated AFP suggests liver or germ cell tumors, prompting imaging or biopsy. Normal levels may require serial monitoring.
Specialist Consultation: Consult an oncologist for result interpretation. Hepatology referral is advised for liver cancer cases.
Additional Supporting Tests: CT/MRI, biopsy, or other tumor markers (e.g., CEA) to confirm cancer diagnosis.
Test Limitations: Non-specific AFP elevation requires clinical correlation. Non-secreting tumors may not elevate AFP.
References: NCCN Oncology Guidelines, 2023; Llovet JM, Lancet Oncology, 2022.
